Elsevier Science, Inc.

SHERPA: Unknown

People

  1. Hudis
    Hudis
  2. Robson
    Robson
  3. Dang
    Dang
  4. Norton
    Norton
  5. Offit
    Offit
  6. Bromberg
    Bromberg
  7. Berger
    Berger
  8. Goldfarb
    Goldfarb
  9. Ladanyi
    Ladanyi
  10. Mandelker
    Mandelker

Groups

  1. Breast Medicine Service (87)
  2. Department of Medicine (87)
  3. Solid Tumor Oncology Division (87)
  4. Survivorship Research (55)
  5. Population Sciences Research Program (36)
  6. GSK Faculty (28)
  7. Epidemiology and Biostatistics (16)
  8. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (15)
  9. Center for Pancreatic Cancer Research (13)
  10. Department of Pathology and Laboratory Medicine (13)
Search Within
  1. "Breast Medicine Service"
Formats
  1. Journal Article (52)
  2. Meeting Abstract (32)
  3. Editorial (1)
  4. Guidelines (1)
  5. Review (1)
Groups
  1. Breast Medicine Service (87)
  2. Department of Medicine (87)
  3. Solid Tumor Oncology Division (87)
  4. Survivorship Research (55)
  5. Population Sciences Research Program (36)
  6. GSK Faculty (28)

More Groups

People
  1. Clifford Hudis (17)
  2. Mark Robson (15)
  3. Larry Norton (11)
  4. Chau Dang (10)
  5. Kenneth Offit (9)
  6. Jacqueline Bromberg (8)

More People

Years
  1. 2025 (2)
  2. 2024 (6)
  3. 2023 (8)
  4. 2022 (2)
  5. 2021 (4)
  6. 2020 (8)

More Years

Publications
  1. Lancet Oncology (15)
  2. Lancet (14)
  3. Journal of Molecular Diagnostics (8)
  4. Critical Reviews in Oncology/Hematology (7)
  5. Journal of Vascular and Interventional Radiology (7)
  6. Journal of the American College of Cardiology (7)

More Publications

Results (87)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer: A first-in-human, single-centre, phase 1 trial
    Journal Article

    Lou, E.; Choudhry, M. S.; Starr, T. K.; Folsom, T. D.; Bell, J.; Rathmann, B.; DeFeo, A. P.; Kim, J.; Slipek, N.; Jin, Z.; more...
    Lancet Oncology (2025)

    Fulltext@MSK | Save
  • ACR Appropriateness Criteria® Imaging of Ductal Carcinoma in Situ (DCIS)
    Guidelines

    Kuzmiak, C. M.; Sharpe, R. E. Jr; Lewin, A. A.; Weinstein, S. P.; Blinder, V.; Dibble, E. H.; Dodelzon, K.; Dogan, B. E.; Paulis, L. V.; Plichta, J. K.; more...
    Journal of the American College of Radiology (2025)

    Fulltext@MSK | Save
  • Neoadjuvant immunotherapy in patients with early-stage, high-risk, ER+/HER2-breast cancer: Physician practices, therapy choice, and barriers among us oncologists
    Meeting Abstract

    Aggarwal, P.; Van Doren, B.; Jeune-Smith, Y.; Jennings-Zhang, L.; Bone, R. N.; Sadeghi, S.; Iyengar, N. M.; Feinberg, B.
    Value in Health (2024)

    Fulltext@MSK | Save
  • Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): One cohort of a phase 2, multicentre, open-label, non-comparative study
    Journal Article

    Rugo, H. S.; Lerebours, F.; Ciruelos, E.; Drullinsky, P.; Ruiz-Borrego, M.; Neven, P.; Park, Y. H.; Prat, A.; Bachelot, T.; Juric, D.; more...
    Lancet Oncology (2024)

    Fulltext@MSK | Save
  • Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): Patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial
    Journal Article

    Oliveira, M.; Rugo, H. S.; Howell, S. J.; Dalenc, F.; Cortes, J.; Gomez, H. L.; Hu, X.; Toi, M.; Jhaveri, K.; Krivorotko, P.; more...
    Lancet Oncology (2024)

    Fulltext@MSK | Save
  • The impact of previous therapy on overall-survival in registration clinical trials for 1st line metastatic breast cancer a systemic review
    Journal Article

    Remilah, A. A.; Krayim, B.; Amir, E.; Tibau, A.; Robson, M. E.; Abuhadra, N.; Chen, Y.; Shepshelovich, D.; Goldvaser, H.
    Critical Reviews in Oncology/Hematology (2024)

    Fulltext@MSK | Save
  • Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer
    Review

    Browne, I. M.; André, F.; Chandarlapaty, S.; Carey, L. A.; Turner, N. C.
    Lancet Oncology (2024)

    Fulltext@MSK | Save
  • Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): An open-label, randomised, controlled, phase 2 study
    Journal Article

    Tsai, C. J.; Yang, J. T.; Shaverdian, N.; Patel, J.; Shepherd, A. F.; Eng, J.; Guttmann, D.; Yeh, R.; Gelblum, D. Y.; Namakydoust, A.; more...
    Lancet (2024)

    Fulltext@MSK | Save
  • Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): A randomised, open-label, multicentre, phase 3 trial
    Journal Article

    Rugo, H S.; Bardia, A.; Marmé, F.; Cortés, J.; Schmid, P.; Loirat, D.; Trédan, O.; Ciruelos, E.; Dalenc, F.; Gómez Pardo, P.; more...
    Lancet (2023)

    Fulltext@MSK | Save
  • New frontiers in the role of locoregional therapies in breast cancer: Proceedings from the Society of Interventional Radiology Foundation Research Consensus Panel
    Editorial

    Daye, D.; Panagides, J.; Norton, L.; Ahmed, M.; Fukuma, E.; Ward, R. C.; Gomez, D.; Kokabi, N.; Vogl, T.; Abi-Jaoudeh, N.; more...
    Journal of Vascular and Interventional Radiology (2023)

    Fulltext@MSK | Save